Aspects of inflammatory bowel disease during the COVID-19 pandemic and general considerations

León-Rendón, Jorge Luis De; Hurtado-Salazar, C.; Yamamoto-Furusho, J.K.

doi:10.1016/j.rgmxen.2020.05.001

Cited by 11 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, the International Organization for the study of Inflammatory Bowel Disease advises that maintenance therapies should not be withheld 9 . Thus, patients shall be vaccinated as soon as possible 155 and, whenever possible, the vaccine should be administered to stable patients, before the start of immunosuppression and under a dose of corticosteroids lower than 20 mg of prednisolone a day (or equivalent), as systemic corticosteroids are known to have immunosuppressive effect above this dosage 164 . This does not exclude the need to consider comorbidities, age, health condition, and risk exposition to COVID‐19, prior to vaccine administration.…”

Section: Covid‐19 Vaccines: Where Are We Now?mentioning

confidence: 99%

“… 9 Thus, patients shall be vaccinated as soon as possible 155 and, whenever possible, the vaccine should be administered to stable patients, before the start of immunosuppression and under a dose of corticosteroids lower than 20 mg of prednisolone a day (or equivalent), as systemic corticosteroids are known to have immunosuppressive effect above this dosage . 164 This does not exclude the need to consider comorbidities, age, health condition, and risk exposition to COVID‐19, prior to vaccine administration. With the objective of guiding physicians worldwide, we, herein, propose a flow‐chart for SARS‐CoV‐2 vaccination, in IBD adult patients (Figure 2 ).…”

Section: Covid‐19 Vaccines: Where Are We Now?mentioning

confidence: 99%

See 1 more Smart Citation

COVID‐19 in gastroenterology: Where are we now? Current evidence on the impact of COVID‐19 in gastroenterology

et al. 2021

View full text Add to dashboard Cite

Background The COVID‐19 pandemic has created unprecedented challenges in all fields of society with social, economic, and health‐related consequences worldwide. In this context, gastroenterology patients and healthcare systems and professionals have seen their routines changed and were forced to adapt, adopting measures to minimize the risk of infection while guaranteeing continuous medical care to chronic patients. Objective At this point, it is important to evaluate the impact of the pandemic on this field to further improve the quality of the services provided in this context. Methods/Results/Conclusion We performed a literature review that summarizes the main aspects to consider in gastroenterology, during the pandemic crisis, and includes a deep discussion on the main changes affecting gastroenterology patients and healthcare systems, anticipating the pandemic recovery scenario with future practices and policies.

show abstract

Section: Covid‐19 Vaccines: Where Are We Now?mentioning

confidence: 99%

Section: Covid‐19 Vaccines: Where Are We Now?mentioning

confidence: 99%

COVID‐19 in gastroenterology: Where are we now? Current evidence on the impact of COVID‐19 in gastroenterology

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Thus, patients with IBD do not appear to be at greater risk of infection by SARS-CoV-2 compared to the general population, and current treatments are not associated with worse prognosis. However, clinicians should be cautious about the use of systemic steroids for treatment of COVID-19 [66] .…”

Section: Sars-cov-2mentioning

confidence: 99%

Vaccinations in patients with inflammatory bowel disease

Macaluso

Liguori

Galli

2021

Digestive and Liver Disease

View full text Add to dashboard Cite

Treatment of inflammatory bowel disease (IBD) frequently requires administration of immunosuppressive therapies, which increases susceptibility to a number of infectious pathogens. However, many infections can be prevented by correct and appropriate utilization of vaccinations. While several guidelines have been published on vaccination schedules in patients with IBD, vaccination rates remain suboptimal and even lower than those in the general population. This is due to many factors including poor awareness of the importance of vaccines by gastroenterologists and general practitioners as well as potential prejudices of patients regarding the safety and benefits of vaccines. With the aim of increasing awareness about the key role of immunization in the management of patients with IBD, the present review examines the existing literature relating to the main vaccinations and their application in these patients. We also summarize current evidence in order to provide clinicians with an easy source of reference for the principal recommendations for prevention of infectious diseases in patients with IBD. In addition, the recommendations about traveling for IBD patients are briefly explored. Lastly, since it is important for gastroenterologists to be aware of recommendations on vaccination, we recommend implementing educational programs to ensure compliance with current guidelines.

show abstract

“…When possible, complex IBD surgeries might be postponed but emergency procedures should continue to be managed as part of routine care. (108) AGA recommends that the evaluation of IBD with dysplasia must not be postponed.…”

Section: Ibd and Covid-19mentioning

confidence: 99%

COVID-19 and Alimentary Tract: Current Evidence and Recent Recommendations

Yousif

2021

Al-Kindy Col. Med. J

View full text Add to dashboard Cite

The pandemic of coronavirus disease 2019 (COVID-19), first reported in China, in December 2019 and since then the digestive tract involvement of COVID-19 has been progressively described. In this review, I summed recent studies, which have addressed the pathophysiology of COVID-19-induced gastrointestinal symptoms, their prevalence, and bowel pathological and radiological findings of infected patients. The effects of gut microbiota on SARS-CoV-2 and the challenges of nutritional therapy of the infected patients are depicted. Moreover, I provide a concise summary of the recommendations on the management of inflammatory bowel disease, colorectal cancer, and performing endoscopy in the COVID era. Finally, the COVID pancreatic relation was explored. Conclusions: digestive symptoms in COVID-19 patients can be the only manifestation and they may be correlated with worse clinical outcomes. The likelihood of fecal-oral transmission of COVID-19 has significant consequences and requires further research. A clear link may exist between the gut microbiome and COVID-19 progression and it may have a therapeutic and prognostic value. No evidence for an increased frequency of covid-19 cases in IBD and stopping immunosuppressive medications is not advised. Triage and risk assessment of patients with suspected or confirmed COVID-19 before endoscopy is essential; deferral of elective endoscopies should be considered.

show abstract

Aspects of inflammatory bowel disease during the COVID-19 pandemic and general considerations

Cited by 11 publications

References 31 publications

COVID‐19 in gastroenterology: Where are we now? Current evidence on the impact of COVID‐19 in gastroenterology

COVID‐19 in gastroenterology: Where are we now? Current evidence on the impact of COVID‐19 in gastroenterology

Vaccinations in patients with inflammatory bowel disease

COVID-19 and Alimentary Tract: Current Evidence and Recent Recommendations

Contact Info

Product

Resources

About